4 April 2013
New Hope for Lung cancer Sufferers
From Islamabad, there appears to be new hope for lung cancer sufferers who have stopped responding to chemotherapy. A new drug, with experimental name LY2181308 aims to stop the growth of deadly malignant tumors by blocking proteins that allow them to develop. It could lead to new treatments for patients with advanced stage 4 lung cancer and give them longer to live.
You can read more here
or
Return to Lung Cancer News Front Page
31 March 2013
Should there be age limits on lung cancer surgery?
Such is the question posed by Dr Lynne Eldridge when analyzing if surgery just becomes too risky after a certain age. Well, results of analysis were surprising. While older patients did not tolerate some of the more aggressive treatments available to younger patients, and they did suffer more complications, they did live longer.
You can read more about this here
or
Return to Lung Cancer News Front Page
31 March 2013
In the State of New South Wales, Australia, "Listen out for lung cancer"campaign has kicked off with ads running across TV, radio and newspapers. It aims to raise awareness in high risk groups such as Indigenous (Aboriginal), Arabic, Chinese and Vietnamese speaking people. Research has shown poor awareness of the symptoms of the disease within these groups, as well as misconceptions about visiting a doctor.
You can more about this here
or
Return to Lung Cancer News Front Page
30 March 2013
Possible new treatment for Brain Metastases associated with Lung Cancer
Until now, other than surgery or radiotherapy to combat brain metastases associated with lung cancer, there have not been any treatment options available. However, researchers at MedUni Vienna, in collaboration with the University of Heidelberg, may have changed that. Results of the studies, which have been published in the highly respected journal Lung Cancer, report changes made to the ALK gene associated with brain metastases of lung cancers, and not just the tumor itself. The ALK gene is the protein that allows cancers to survive and thrive.
You can read more about this here
or
Return to Lung Cancer News Front Page
29 March 2013
Targeting Hsp90 in non-small cell lung cancer (NSCLC)
In the cancer world Hsp90 is responsible for helping a number of different cancers to survive and thrive. A new medication, Ganetespib, has shown during trials that it is able to knock out Hsp90 in patients with certain types of lung cancers, as well as disable another protein responsible for lung cancer called anaplastic lymphoma kinase (ALK). The medication has been tipped as being able to help patients who no longer react to their current NSCLC medication.
Read more about this here
or
Return to Lung Cancer News Front Page
29 March 2013
Networks may reveal how lung cancer spreads
Doctors in San Diego, USA, have drawn parallels between networking websites and the transmission of digital cell phone networks and the way in which lung cancer spreads in the human body. It is hoped that it may lead to better treatment for patients. By using adapted technology developed by Google's co-founder Andrew Viterbi, doctors were able to identify that some parts of the body were "spreaders" of lung cancer, while others were "sponges" and did not spread the disease so easily
Read more about this here and here
or
Return to Lung Cancer News Front Page
28 March 2013
NHS refuses drug as "too expensive".
In the United Kingdom, The National Health Service (NHS) Watchdog has disallowed access by lung cancer sufferers to a drug called Crizotinib which is said to be twice as effective as chemotherapy, because it is too expensive due to a lack of evidence of the benefits. The cost benefit analysis, as deemed by the NHS, does not stack up. Although it stops non-small cell lung cancer for up to 8 months, it costs around
View the Original article
No comments:
Post a Comment